12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bavituximab: Additional Phase IIb data

Peregrine said an internal review determined that the previously-announced discrepancies in data from a Phase IIb trial were isolated to the placebo and 1 mg/kg bavituximab plus docetaxel treatment arms and did not affect the 3 mg/kg bavituximab plus docetaxel arm. Peregrine said the data also showed that patients in the 3 mg/kg bavituximab plus docetaxel arm had "favorable" tumor response rates, PFS and OS as compared to the...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >